Drugs, Alcohol, Pregnancy, and the Child Series
Over one million children in this country per year are delivered to women who have used alcohol, tobacco, marijuana, or illicit drugs during pregnancy. This webinar series will explore the biological and environmental factors for mothers, children and families that impact the ultimate development of children affected by prenatal substance exposure and provide an overview of family- and school-based intervention strategies that can promote long-term growth and development of this high-risk population of children.
Wednesday, July 19, 2023
12:00 p.m.–1:30 p.m.
Webinar
Neonatal abstinence syndrome [NAS] is a diagnosis that originally was restricted to infants going through withdrawal due to the effects of prenatal opioid exposure. However, over time, the term began to be applied to infants with jitteriness and irritability following prenatal exposure to other substances. A new term, Neonatal Opioid Withdrawal Syndrome (NOWS), recently emerged to ensure specificity in the diagnosis of infants affected by prenatal exposure to opioids. Whichever term is used, how do clinicians differentiate the effects of and infants’ dependence on opioids from infants with neurobehavioral deficits due to non-opioid exposure. This session will address that question and provide an effective approach to diagnosing NOWS in the newborn infant.
Learning objectives:
At the completion of this session, participants will be able to:
This course is provided by Connecticut Hospital Association.
For more information please contact CHA Education Services on Phone # 203-294-7263 or by email address educationservices@chime.org.
Starts On
Registration Begins
Registration Ends